Coherus Oncology, Inc. (CHRS)
1.04
-0.03
(-2.80%)
USD |
NASDAQ |
Oct 12, 12:00
Coherus Oncology Enterprise Value : 114.15M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 114.15M |
| October 08, 2026 | 114.15M |
| October 07, 2026 | 104.89M |
| October 06, 2026 | 107.98M |
| October 05, 2026 | 121.88M |
| October 02, 2026 | 128.06M |
| October 01, 2026 | 128.06M |
| September 30, 2026 | 135.78M |
| September 29, 2026 | 131.15M |
| September 28, 2026 | 124.97M |
| September 25, 2026 | 123.42M |
| September 24, 2026 | 129.60M |
| September 23, 2026 | 143.50M |
| September 22, 2026 | 149.68M |
| September 21, 2026 | 160.50M |
| September 18, 2026 | 157.41M |
| September 17, 2026 | 138.87M |
| September 16, 2026 | 137.32M |
| September 15, 2026 | 154.32M |
| September 14, 2026 | 169.76M |
| September 11, 2026 | 154.32M |
| September 10, 2026 | 155.86M |
| September 09, 2026 | 152.77M |
| September 08, 2026 | 160.50M |
| September 04, 2026 | 168.22M |
| Date | Value |
|---|---|
| September 03, 2026 | 160.50M |
| September 02, 2026 | 168.22M |
| September 01, 2026 | 160.50M |
| August 31, 2026 | 157.41M |
| August 28, 2026 | 166.67M |
| August 27, 2026 | 174.40M |
| August 26, 2026 | 172.85M |
| August 25, 2026 | 160.50M |
| August 24, 2026 | 158.95M |
| August 21, 2026 | 168.22M |
| August 20, 2026 | 152.77M |
| August 19, 2026 | 154.32M |
| August 18, 2026 | 155.86M |
| August 17, 2026 | 126.51M |
| August 14, 2026 | 134.24M |
| August 13, 2026 | 124.97M |
| August 12, 2026 | 129.60M |
| August 11, 2026 | 135.78M |
| August 10, 2026 | 140.41M |
| August 07, 2026 | 145.05M |
| August 06, 2026 | 144.28M |
| August 05, 2026 | 172.85M |
| August 04, 2026 | 177.49M |
| August 03, 2026 | 171.31M |
| July 31, 2026 | 166.67M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enanta Pharmaceuticals, Inc. | 356.53M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.35M |
| Revenue (Quarterly) | 14.31M |
| Total Expenses (Quarterly) | 47.65M |
| EPS Diluted (Quarterly) | -0.1312 |
| Gross Profit Margin (Quarterly) | 64.33% |
| Profit Margin (Quarterly) | -233.1% |
| Earnings Yield | -98.19% |
| Normalized Earnings Yield | -96.97 |